
Overview
Adam Winer is of counsel in the firm's Emerging Growth Company practice and is based in the New York office.
Adam focuses on the representation of venture capital funds and emerging growth companies. He counsels clients in connection with capital raising transactions, including venture capital and growth equity financings. He also enjoys helping clients to design and execute significant transactions, including mergers and acquisitions, stockholder liquidity transactions, joint ventures, spinoffs, licensing transactions and reorganizations. Adam also supports emerging growth company clients with respect to general corporate matters.
Prior to joining Paul Hastings, Adam practiced in the New York office of another international law firm, where he advised on a wide range of complex corporate transactions.
Adam received his law degree from the New York University School of Law in 2018, where he served as a notes editor for the New York University Law Review. He received his B.A., First Class Honors, in Philosophy from McGill University in 2013.
Representations
Investor Representations
- Adam has represented a number of venture capital funds in connection with their investment activities, including Deerfield Management, Blackstone Life Sciences, Smash Capital, Infinity Ventures, Digitalis Ventures, IAG Capital and Black Ivy.
Company Representations
- Galway Sustainable Credit in its $250 million financing by Macquarie.
- Loadsmart in its $200 million Series D financing.
- CINQ Care in various equity financing transactions.
- Annexus Health in its $33 million Series B financing.
- Ivy Energy in its $18 million Series A financing.
- Curbwaste in its $10 million Series A financing and $28 million Series B financing.
- Hungryroot in its $40 million Series A financing.
- Jaguar Gene Therapy in its capital raising activities.
- Offchain Labs in its acquisition of Prysmatic Labs.
- Fairhaven Health in its acquisition by Blue Root Health, a portfolio company of North Castle Partners.
News
- Paul Hastings Advises Deerfield Management in Series Seed Financing for Atlas Data Storage - May 6th, 2025
- Paul Hastings Advised Blackstone Life Sciences in Series B Financing of AvenCell Therapeutics - October 23rd, 2024
- Paul Hastings Advised Galway Sustainable Credit in Significant Investment from Macquarie Asset Management - June 15th, 2023